Novelty Nobility is a private biotech company developing antibody-based therapeutics targeting novel angiogenesis pathways to combat diseases associated with abnormal blood vessel growth. Their PREXISE-D platform focuses on overcoming drug resistance through antibody-drug conjugates, enhancing treatment efficacy for patients.
Funding
$43.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, particularly in oncology and ophthalmology, are associated with abnormal angiogenesis and can develop resistance to existing treatments, requiring new therapeutic approaches to improve patient outcomes. Current treatments may not effectively target novel angiogenesis pathways or overcome drug resistance mechanisms.
Solution
Novelty Nobility is developing antibody-based therapeutics, including antibody-drug conjugates (ADCs), that target novel angiogenesis pathways to treat diseases with abnormal blood vessel growth and overcome drug resistance. Their PREXISE-D platform enables the design and discovery of fit-for-purpose antibodies, tailoring the therapeutic modality to the specific disease mechanism. The company's lead candidate, NN3201, is a first-in-class c-Kit targeting ADC currently in Phase 1 clinical trials for advanced solid tumors. Novelty Nobility is also developing bispecific antibodies and exploring collaborations to develop novel ADC platform technologies.
Target Audience
The primary target audience includes patients with advanced solid tumors and retinal diseases, as well as pharmaceutical companies seeking novel antibody therapeutics and ADC technologies.
Features
- PREXISE-D platform for fit-for-purpose antibody design and discovery
- Focus on novel angiogenesis targets in ophthalmology and oncology
- Development of antibody-drug conjugates (ADCs) to overcome drug resistance
- NN3201: a c-Kit targeting ADC in Phase 1 clinical trials for advanced solid tumors including gastrointestinal stromal tumors (GIST), adenoid cystic carcinoma (ACC), and small cell lung cancer (SCLC)
- Bispecific antibody candidate NN4101 targeting c-Kit and VEGF for vascular retinal diseases
- Collaborations to develop novel ADC platform technologies